External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality read more…
Category Archives: Published Articles
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path) Fenizia, F., Wolstenholme, N., Fairley, J.A. et al. Virchows Arch (2021). You can access the article here: https://rdcu.be/ciMl7 Abstract While tumour mutation burden (TMB) is emerging as a possible biomarker for immune-checkpoint inhibitors (ICI), methods for testing have not been standardised as yet. read more…
Unlocking the potential of precision medicine in Europe – Improving cancer care through broader access to quality biomarker testing
Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the read more…
New article: Biomarker testing in oncology
Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to read more…
Article published in The Pathologist
IQN Path, in collaboration with Ventana Medical Systems, have published an article in The Pathologist entitled ‘A Quality Undertaking – Connecting EQA and industry to ensure quality diagnostic testing’. This short article explores the difficulties in standardisation for accuracy and precision in the EQA process and ways that IQN Path is working in collaboration with read more…
New Article in ESMO Open
In April this year, for the fifth consecutive year, representatives of all stakeholders involved in promoting accurate diagnostic testing for anticancer drug selection gathered in Naples in order to optimise the chance that patients will have an appropriate test which forms the basis for the decision of administering targeted treatment. The article published on ESMO read more…
New WHO Publication
In September last year IQN Path was invited to Geneva to the World Health Organization to represent the viewpoint of pathology in an international discussion on external quality assessment. This meeting resulted in a new publication from the WHO entitled ‘WHO manual for organising a national external quality assessment program for health laboratories and other read more…